Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MOO.0000000000001047 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Eosinophilic Otitis Media: A Six-Month Observational Study.
Medicina (Kaunas)
August 2025
Unit of Otorhinolaryngology, Department of Adult and Development Age Human Pathology "Gaetano Barresi", University of Messina, Via Consolare Valeria 1, 98125 Messina, Italy.
Chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic otitis media (EOM) are frequently co-existing eosinophilic disorders related to type 2 inflammation, which significantly impair the quality of life of patients. Dupilumab, a monoclonal antibody targeting the IL-4 receptor alpha and anti-IL-13, has demonstrated a promising profile of efficacy and safety in the treatment of CRSwNP; however, evidence on its role in concomitant EOM and CRSwNP remains limited in the literature. This study aims to evaluate the clinical efficacy of dupilumab in patients with concomitant CRSwNP and EOM over a six-month observational period.
View Article and Find Full Text PDFTransfacial Removal of a Retained Crossbow Arrow to the Head: A Multidisciplinary Approach.
Ear Nose Throat J
August 2025
Department of Otolaryngology - Head and Neck Surgery, University of Washington, Seattle, WA, USA.
We present a case of a 49 year-old male who suffered from a homicide attempt with a crossbow arrow, resulting in a retained foreign body through his mandible, pterygoids, nasopharynx, and parotid gland. The patient was being managed conservatively with antibiotics to manage symptoms of recurrent infections prior to transfer to our center. The patient developed worsening congestion, foul drainage from the arrow exit wound, as well as developing worsening facial pain.
View Article and Find Full Text PDFAtopic dermatitis occurrence and progression and allergen immunotherapy: A real-world, retrospective cohort study in Germany.
World Allergy Organ J
August 2025
Pediatric Pulmonology and Allergology, Kinderzentrum Dresden-Friedrichstadt, Dresden, Germany.
Background: Allergen immunotherapy (AIT) represents the sole causal and preventive disease-modifying therapy currently available for allergic diseases. However, it must be acknowledged that controlled studies feature inherent results bias due to specific criteria and monitoring during the study. This real-world evidence (RWE) study was therefore designed to analyse data on large longitudinal prescriptions of different types of AIT in order to evaluate the therapeutic effect on the progression and onset of atopic dermatitis (AD).
View Article and Find Full Text PDFPost-marketing safety profile of Ertugliflozin: Insights from a real-world pharmacovigilance analysis based on the FAERS database.
Eur J Pharmacol
August 2025
Center of Health Administration and Development Studies, Hubei University of Medicine, Shiyan, Hubei, 442000, China. Electronic address:
Background: Ertugliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, is approved for glycemic control in type 2 diabetes mellitus (T2DM). Although clinical trials confirm its efficacy, real-world data suggest potential safety concerns. This study evaluates the post-marketing safety profile of ertugliflozin using the FDA Adverse Event Reporting System (FAERS).
View Article and Find Full Text PDFConsensus from European experts on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: Results from the OverSEA Delphi study.
J Allergy Clin Immunol Glob
November 2025
Center for Rhinology and Allergy, Wiesbaden, Germany.
Background: Managing patients with severe asthma with an eosinophilic phenotype (SEA) with comorbid respiratory conditions such as chronic rhinosinusitis with nasal polyps (CRSwNP) continues to encounter significant challenges and lack of coordinated management among treating physicians.
Objective: The OverSEA study aims to provide insights into current clinical practices and formulate recommendations for managing these patients.
Methods: The two-round Delphi survey, conducted March-June 2023, was developed by a multidisciplinary 11-member Scientific Committee including pulmonologists, allergists, and ear, nose and throat specialists, and involved 205 experts from these specialties across 8 European countries.